Tokyo, April 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061040) titled 'Validation of atrial fibrillation screening strategies in patients with ischemic heart disease using artificial intelligence electrocardiography (CVI ARO 21 Study)' on April 1.
Study Type:
Observational
Primary Sponsor:
Institute - The Cardiovascular Institute
Condition:
Condition - Ischemic heart disease
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To Evaluate the availability of seal-designed Holter ECG in patients with ischemic disease and high risk for atrial fibrillation by real-time risk alert derived from artificial intelligence enhanced sinus rhythm ECG.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
= 0.8.
(2) Out-hospital patients with AI-ECG enhanced AF risk score >= 0.8 and Suita risk score >=12.
Key exclusion criteria - Patients who do not consent to research participation.
Target Size - 197
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2024 Year 08 Month 02 Day
Date of IRB - 2024 Year 08 Month 26 Day
Anticipated trial start date - 2025 Year 01 Month 15 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069560
Disclaimer: Curated by HT Syndication.
